

Issuing Platelets - Clinical Guideline

Reference No: CG-T/2025/176

GUIDELINES FOR ISSUING PLATELETS

Requests for platelets which fall within these guidelines can be issued by Blood Bank staff. Any requests falling outsides these guidelines should be referred to Dr McKernan (or other Consultant Haematologist/SpR).

Platelet transfusion: principles, risks, alternatives and best practice

Platelet transfusions are an essential component in the management of selected patients with thrombocytopenia. However they need to be used judiciously as they are a limited resource and are not risk free.

Classification of conditions which may require platelet transfusion	Platelet transfusion: Indication categories and contraindications
Bone marrow failure (BMF). Reversible associated with treatable disease and/or chemotherapy and occasionally chronic (irreversible) BMF e.g. myelodysplastic syndromes	 Prophylactic (WHO bleeding grade 0 or 1) to prevent bleeding > Routine use in non-bleeding patients > In the presence of additional risk factors for bleeding e.g. sepsis or abnormalities of haemostasis
Peripheral platelet consumption/destruction e.g. disseminated intravascular coagulation and immune thrombocytopenia	Pre-procedure to prevent bleeding expected to occur during surgery/invasive procedure
Thrombocytopenia in critical care	Therapeutic (WHO bleeding grade >2) to treat active bleeding
Abnormal platelet function. Inherited or acquired disorders e.g. anti-platelet agents, uraemia	Contraindications to platelet transfusion unless life-threatening haemorrhage Thrombotic Thrombocytopenic Purpura (TTP)

Risks associated with platelet transfusion

Reduced effectiveness of future platelet transfusion


Alloimmunisation Adverse effects

Febrile non-haemolytic transfusion reactions (FNHTR) and allergic reactions (including mild), reported incidence up to 3%. May require investigation to exclude other causes and prolong hospital stay.

Estimated risk of moderate/severe reactions and infection transmission:

FNHTR	• 1 in 6,000		
Allergic	• 1 in 6,000		
Haemolysis	• 1 in 600,000		
Bacterial sepsis	Rare since bacterial screening 2010		
Transfusion Related Acute Lung Injury	• Less than 1 in 1,000,000		
Hepatitis B infection	• 1 in 1,000,000		
Hepatitis C infection	• 1 in 30,000,000		
HIV infection	• 1 in 7,000,000		

Prior to prescribing a platelet transfusion consider:



Possible alternatives to platelet transfusion:

- Apply surface pressure after superficial procedures and correct surgical causes for bleeding
- Surgical patients expected to have at least a 500 ml blood loss, use tranexamic acid (TXA) unless contraindicated
- Trauma patients who are bleeding/ at risk of bleeding, early use of TXA
- Severe bleeding replace fibrinogen if plasma concentration less than 1.5 g/L
- Anti-platelet agents discontinue or if urgent procedure/bleeding use TXA if risk/benefit would support Uraemia with bleeding or preprocedure dialyse, correct anaemia, consider desmopressin
- Inherited platelet function disorders specialist haematology advice required. Consider desmopressin
- Chronic BMF with bleeding consider TXA





Indications for use of platelet transfusions in adults

Indication	Transfusion indicated
Provinsional (No blooding or WIIO grade 4)	(threshold)/not indicated
Prophylactic use (No bleeding or WHO grade 1) One adult dose required	
 Reversible bone marrow failure (BMF) including allogeneic stem cell transplant 	10 x 10%
- Reversible BMF with autologous stem cell transplant (consider no prophylaxis)	10 x 10%
- Critical illness	10 x 10%
- Chronic BMF receiving intensive therapy	10 x 10 ⁹ /L
 Chronic BMF to prevent persistent bleeding of grade > 2 	Count variable
 Chronic stable BMF, abnormal platelet function, platelet consumption/ destruction (e.g. DIC, TTP) or immune thrombocytopenia (ITP, HIT, PTP) 	Not indicated
Prophylactic use in the presence of risk factors for bleeding (e.g. sepsis, antibiotic treatment, abnormalities of haemostasis)	
- Reversible/chronic bone marrow failure or critical care	10 to 20 x 10%L
- Abnormal platelet function, platelet consumption/destruction, immune thrombocytopenia	Not indicated
Platelet transfusion preprocedure	
 Central venous catheter (CVC) excluding PICC line 	20 x 10º/L
- Lumbar puncture	40 x 10º/L
- Percutaneous liver biopsy	50 x 10º/L
- Major surgery	50 x 10º/L
 Epidural anaesthesia, insertion & removal 	80 x 10º/L
 Neurosurgery or ophthalmic surgery involving the posterior segment of the eye 	100 x 10%L
Bone marrow aspirate or trephine biopsies, PICC line insertion, traction removal of central venous catheters (CVCs), cataract surgery	Not indicated
Specific clinical conditions preprocedure-see below for indications	
Therapeutic use (Bleeding WHO grade 2 or above)	
-Severe bleeding	50 x 10%L
-Multiple trauma, brain or eye injury, spontaneous intracerebral haemorrhage	100 x 10%L
-Bleeding (WHO grade >2) but not severe	30 x 10º/L
-Bleeding in specific clinical conditions – see the next table for indications	
Specific clinical conditions	
Platelet function defect	
 Congenital – Preprocedure or therapeutic use. When alternative therapy contraindicated or ineffective. Directed by specialist in haemostasis. 	Count Variable

Acquired (anti-platelet agents, uraemia)- only indicated for severe bleeding

Disseminated intravascular bleeding Preprocedure or therapeutic use. Consider threshold counts above but may not be Use preprocedure or achievable and individual case review required therapeutic threshold as guide Thrombotic thrombocytopenic purpura Platelet transfusion contraindicated unless life-threatening bleeding Count Variable Immune thrombocytopenia (ITP, HIT, PTP). Preprocedure when other therapy ineffective/procedure urgent or to treat Use preprocedure or severe bleeding. Consider threshold counts above but may be unachievable or unnecessary therapeutic threshold and individual case review required as guide Abbreviations Disseminated intravascular coagulation (DIC), peripherally inserted central catheter (PICC), thrombotic thrombocytopenic purpura (TTP), primary immune thrombocytopenia (ITP),

heparin-induced thrombocytopenia (HIT), post-transfusion purpura (PTP)

Documentation Controls

Reference Number	Version:	2	Status Final				
CG-T/2025/176							
Version /	Version	Date	Author	Rea	Reason		
Amendment History	1	2014	Consultant Haematologist	Gui	Guideline new to Koha		
	1.1	2021	Consultant haematologist		Reviewed with no changes		
	2	2025	Consultant Haematologist	Rev	Review and update		
Intended Recipier	nts: UHDB (Clinical staff					
locally disseminated. Development of Guideline:Dr Firas Al-Kaisi Job Title: Consultant Haematologist							
Consultation with:							
Linked Documents: BSH Platelet Transfusion Guidelines 2021							
Keywords:Platelets							
Business Unit Sign Off			Group:Haematology Date:Dec 2024				
Divisional Sign O	onal Sign Off			Group:CDCS Division Date:Feb 2025			
Date of Upload			February 2025				
Review Date				February 2028			
Contact for Review Consultant Haematologist							